Efficacy of HOSPSL 577nm laser in Melasma Treatment

An efficacy of high-power optically pumped semiconductor laser (HOPSL) 577 nanometers in the treatment of melasma, A pilot study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210618003

Enrollment

Registered

2021-06-18

Start date

2015-05-28

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with melasma that did not response to at least 2% hydroquinone cream-containing regimen after 3 months melasma laser 577nm

Interventions

Patients in this study continued the use of their topical melasma treatment that applied on both side of the face. After randomization, intervention with HOSPL 577nm laser would be done on one side o

Experimental Device,No Intervention Drug

Topicals + Laser,Topicals only

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 20-65 years old 2. Melasma (Epidermal or mixed type) on both side of face 3. Do not response to at least 2% hydroquinone-containing regimen after at least 3 months usage 4. Fizpatrick skin type III-V 5. Willing to participate and give written informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation 2. Dermatitis or wound on face 3. Has other type(s) of pigmented lesions (such as seborrheic keratosis, lentigines, freckles, Hori's nevus, or nevus of Ota) in the melasma area 4. History of hormonal treatment within 1 month before the study participation 5. Recieve any chemical peelings or laser treatment on the face within 6 months before the study participation

Design outcomes

Primary

Measure	Time frame
Efficacy: melanin and erythema index Baseline, wk2, wk4, wk8, wk12, wk16, wk20, wk28, wk40 Mexameter ,Efficacy: Clinical grading score Baseline, wk2, wk4, wk8, wk12, wk16, wk20, wk28, wk40 mMASI (modified Melasma Area and Severity Index) score,Efficacy: Physician clinical photo evaluation wk2, wk4, wk8, wk12, wk16, wk20, wk28, wk40 Clinical photography,Efficacy: Patient self assessment wk2, wk4, wk8, wk12, wk16, wk20, wk28, wk40 VAS (visual analog scale)	—

Measure

Time frame

Efficacy: melanin and erythema index Baseline, wk2, wk4, wk8, wk12, wk16, wk20, wk28, wk40 Mexameter ,Efficacy: Clinical grading score Baseline, wk2, wk4, wk8, wk12, wk16, wk20, wk28, wk40 mMASI (modified Melasma Area and Severity Index) score,Efficacy: Physician clinical photo evaluation wk2, wk4, wk8, wk12, wk16, wk20, wk28, wk40 Clinical photography,Efficacy: Patient self assessment wk2, wk4, wk8, wk12, wk16, wk20, wk28, wk40 VAS (visual analog scale)

—

Secondary

Measure	Time frame
Safety: Adverse effect evaluation wk2, wk4, wk8, wk12, wk16, wk20, wk28, wk40 Physician evaluation,Pain from laser Baseline, wk4, wk8, wk12, wk16 pain score	—

Countries

Thailand

Contacts

Public ContactSasima Eimpunth

Faculty of Medicine Sirriaj Hospital

doctorsasima@gmail.com024194333

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026